NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INCY?
Source: Newsfilter
- First Approval: NIKTIMVO (axatilimab) has been approved in Australia for the treatment of chronic graft-versus-host disease (cGVHD), becoming the first anti-CSF-1R antibody to receive marketing authorization in the country, marking a significant step in its global rollout.
- Clinical Trial Results: In a study involving 241 patients who had received at least two prior lines of systemic therapy, NIKTIMVO demonstrated an overall response rate of 74%, with 60% of patients maintaining their response at 12 months, indicating its efficacy and potential long-term benefits in treating cGVHD.
- Market Demand: Approximately 600 allogeneic stem cell transplants are performed annually in Australia, with cGVHD affecting 40-50% of recipients; the approval of NIKTIMVO provides a new treatment option for these patients, addressing the urgent need for effective therapies in the market.
- Strategic Partnership: Specialised Therapeutics has entered into an exclusive partnership with Incyte to commercialize NIKTIMVO in Australia, New Zealand, and Singapore, further solidifying its market position in the Asia-Pacific region.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 95.270
Low
73.00
Averages
100.31
High
125.00
Current: 95.270
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
- First Approval: NIKTIMVO (axatilimab) has been approved in Australia for the treatment of chronic graft-versus-host disease (cGVHD), becoming the first anti-CSF-1R antibody to receive marketing authorization in the country, marking a significant step in its global rollout.
- Clinical Trial Results: In a study involving 241 patients who had received at least two prior lines of systemic therapy, NIKTIMVO demonstrated an overall response rate of 74%, with 60% of patients maintaining their response at 12 months, indicating its efficacy and potential long-term benefits in treating cGVHD.
- Market Demand: Approximately 600 allogeneic stem cell transplants are performed annually in Australia, with cGVHD affecting 40-50% of recipients; the approval of NIKTIMVO provides a new treatment option for these patients, addressing the urgent need for effective therapies in the market.
- Strategic Partnership: Specialised Therapeutics has entered into an exclusive partnership with Incyte to commercialize NIKTIMVO in Australia, New Zealand, and Singapore, further solidifying its market position in the Asia-Pacific region.
See More
Incyte Receives FDA Approval for Jakafi XR
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) extended-release tablets have received FDA approval, marking a significant advancement in the treatment of blood disorders for the company.
- Expanded Indications: The drug is indicated for adults with intermediate- or high-risk myelofibrosis, those with polycythemia vera who have had inadequate responses to or are intolerant of hydroxyurea, and patients aged 12 and older with steroid-refractory acute or chronic graft-versus-host disease, showcasing its broad clinical application potential.
- Clinical Study Support: The approval was based on a clinical study demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg immediate-release Jakafi tablet taken twice daily, simplifying the dosing regimen and enhancing patient adherence to treatment.
- Market Launch Date: Jakafi XR will be available for pharmacy orders starting May 8, which is expected to generate new revenue streams for Incyte while strengthening its position in the competitive oncology drug market.
See More
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
Incyte Q1 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Incyte's Q1 non-GAAP EPS of $1.81 beats expectations by $0.47, reflecting a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The total revenue for Q1 reached $1.27 billion, a 20% year-over-year increase, surpassing market expectations by $50 million, indicating robust performance and sustained demand in the biopharmaceutical sector.
- Product Sales Surge: Jakafi® net sales were $758 million, up 7%, while Opzelura® cream and the Hematology and Oncology portfolio saw sales increases of 20% and 116%, respectively, highlighting strong market acceptance and sales potential for new products.
- Positive Future Outlook: Incyte's guidance for total net sales in fiscal year 2026 is projected between $4.77 billion and $4.94 billion, reaffirming sales guidance across all categories, which demonstrates the company's confidence in future growth and sound strategic planning.
See More
Incyte Q1 Earnings Preview and Estimates
- Earnings Announcement Date: Incyte (INCY) is set to announce its Q1 earnings on April 28 before market open, with investors keenly awaiting the results that could impact stock performance.
- Earnings and Revenue Expectations: Analysts estimate an EPS of $1.34, reflecting a 15.5% year-over-year increase, while revenue is projected at $1.22 billion, up 16.2%, indicating the company's ongoing growth potential.
- Historical Performance Review: Over the past two years, Incyte has beaten EPS estimates 38% of the time and revenue estimates 88% of the time, showcasing the company's reliability in earnings announcements.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen no upward revisions but seven downward adjustments, while revenue estimates have experienced two upward revisions and five downward, reflecting a cautious market outlook on the company's future performance.
See More
NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
- First Approval: NIKTIMVO (axatilimab) has been approved in Australia for the treatment of chronic graft-versus-host disease (cGVHD), becoming the first anti-CSF-1R antibody to receive marketing authorization in the country, marking a significant step in its global rollout.
- Clinical Trial Results: In a study involving 241 patients who had received at least two prior lines of systemic therapy, NIKTIMVO demonstrated an overall response rate of 74%, with 60% of patients maintaining their response at 12 months, indicating its efficacy and potential long-term benefits in treating cGVHD.
- Market Demand: Approximately 600 allogeneic stem cell transplants are performed annually in Australia, with cGVHD affecting 40-50% of recipients; the approval of NIKTIMVO provides a new treatment option for these patients, addressing the urgent need for effective therapies in the market.
- Strategic Partnership: Specialised Therapeutics has entered into an exclusive partnership with Incyte to commercialize NIKTIMVO in Australia, New Zealand, and Singapore, further solidifying its market position in the Asia-Pacific region.
See More
Incyte Receives FDA Approval for Jakafi XR
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) extended-release tablets have received FDA approval, marking a significant advancement in the treatment of blood disorders for the company.
- Expanded Indications: The drug is indicated for adults with intermediate- or high-risk myelofibrosis, those with polycythemia vera who have had inadequate responses to or are intolerant of hydroxyurea, and patients aged 12 and older with steroid-refractory acute or chronic graft-versus-host disease, showcasing its broad clinical application potential.
- Clinical Study Support: The approval was based on a clinical study demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg immediate-release Jakafi tablet taken twice daily, simplifying the dosing regimen and enhancing patient adherence to treatment.
- Market Launch Date: Jakafi XR will be available for pharmacy orders starting May 8, which is expected to generate new revenue streams for Incyte while strengthening its position in the competitive oncology drug market.
See More
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
Incyte Q1 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Incyte's Q1 non-GAAP EPS of $1.81 beats expectations by $0.47, reflecting a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The total revenue for Q1 reached $1.27 billion, a 20% year-over-year increase, surpassing market expectations by $50 million, indicating robust performance and sustained demand in the biopharmaceutical sector.
- Product Sales Surge: Jakafi® net sales were $758 million, up 7%, while Opzelura® cream and the Hematology and Oncology portfolio saw sales increases of 20% and 116%, respectively, highlighting strong market acceptance and sales potential for new products.
- Positive Future Outlook: Incyte's guidance for total net sales in fiscal year 2026 is projected between $4.77 billion and $4.94 billion, reaffirming sales guidance across all categories, which demonstrates the company's confidence in future growth and sound strategic planning.
See More
Incyte Q1 Earnings Preview and Estimates
- Earnings Announcement Date: Incyte (INCY) is set to announce its Q1 earnings on April 28 before market open, with investors keenly awaiting the results that could impact stock performance.
- Earnings and Revenue Expectations: Analysts estimate an EPS of $1.34, reflecting a 15.5% year-over-year increase, while revenue is projected at $1.22 billion, up 16.2%, indicating the company's ongoing growth potential.
- Historical Performance Review: Over the past two years, Incyte has beaten EPS estimates 38% of the time and revenue estimates 88% of the time, showcasing the company's reliability in earnings announcements.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen no upward revisions but seven downward adjustments, while revenue estimates have experienced two upward revisions and five downward, reflecting a cautious market outlook on the company's future performance.
See More
